688176 Jiangsu Yahong Meditech
- 6.53
- -0.09-1.36%
Jiangsu Yahong Meditech News
Yahong Medical (688176.SH) approximately 6.8005 million restricted shares will be listed and circulated starting from January 7.
Yahong Pharmaceutical (688176.SH) announced that the restricted shares for this listing circulation are from the company's initial public offering prior to...
Asia Rainbow Pharmaceuticals (688176.SH): Shareholder voluntarily commits to extend the lock-up period of shares.
Glory Holdings reported on December 27 that Yahon Pharmaceutical (688176.SH) announced that it recently received a commitment letter from the company's Shareholders regarding the voluntary extension of the lock-up period for restricted shares. Based on confidence in the company's future development prospects and recognition of its investment value, the company's controlling Shareholder and actual controller Mr. PANKE's concerted actors, Pan-Scientific Holdings Co., Ltd., Taizhou Donghong Enterprise Management Center (Limited Partnership), and Taizhou Yahon Enterprise Management Center (Limited Partnership), a total of three Shareholders, committed to lock up all the shares they Hold prior to the company's initial public offering.
Jiangsu Yahong Meditech Co., Ltd.'s (SHSE:688176) Intrinsic Value Is Potentially 88% Above Its Share Price
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. Report for the Third Quarter of 2024
Yahong Pharmaceuticals accumulated revenue of 0.139 billion yuan in the first three quarters of this year, with two commercialized products continuing to ramp up production.
On the evening of October 29, YAHONG PHARMACEUTICAL (688176.SH) disclosed its third quarter report. The company achieved revenue of 58.4582 million yuan in the third quarter, a year-on-year increase of 1903.16%; for the first three quarters, the cumulative revenue was 0.139 billion yuan, a year-on-year increase of 4537.79%. The revenue growth is mainly attributed to the company starting to sell its drug Pipatinib Tablets (brand name: Dipatte) and Nilotinib Maleate Tablets (brand name: Ouyoubi) in the fourth quarter of 2023. Commercial promotion has steadily progressed during this reporting period, leading to an increase in sales volume.
Yahong Pharmaceutical (688176.SH): The clinical trial application for APL-2302 has been approved by the FDA.
YAHONG Pharmaceuticals (688176.SH) announced that the company has received a notice from the Food and Drug Administration (referred to as the “FDA…
Yaohong Pharmaceuticals (688176.SH): has repurchased 1.4651% of the shares accumulated.
On October 8, Gronghui reported that as of September 30, 2024, YAHONG Pharmaceuticals (688176.SH) has cumulatively repurchased 8,351,322 shares, accounting for 1.4651% of the total share capital. The highest price for repurchase transactions is RMB 6.73 per share, the lowest price is RMB 4.99 per share, and the total funds paid amount to RMB 47.787 million (excluding stamp duty, transaction commissions and other transaction costs).
Jiangsu Yahong Meditech Finishes Phase 2 Trial for Muscle-Invasive Bladder Cancer Pre-Treatment Combo
Yahong Medical (688176.SH): The Phase II clinical trial of APL-1202 oral combination with Toripalimab as neoadjuvant treatment for muscle-invasive bladder cancer has been completed and has shown positive efficacy signals.
On September 25th, Alphamab Oncology announced that the Phase II clinical trial of APL-1202 oral combination with toripalimab monoclonal antibody for muscle-invasive bladder cancer (MIBC) neoadjuvant therapy has completed Phase II clinical stage and achieved positive therapeutic efficacy signals. The main objective of this Phase II clinical trial is to evaluate the safety and efficacy of the combination of APL-1202 and toripalimab monoclonal antibody compared to toripalimab monotherapy as neoadjuvant therapy in MIBC subjects. The study population consists of subjects diagnosed with MIBC for the first time and planning to undergo radical cystectomy, who are intolerant or refuse to receive
Need To Know: Analysts Are Much More Bullish On Jiangsu Yahong Meditech Co., Ltd. (SHSE:688176) Revenues
Yahong Meditech Says APL1702 Drug's Trial Shows Positive Results; Shares Down 3%
Yahong Pharmaceuticals (688176.SH): The results of the APL-1702 international multicenter phase III clinical trial were selected for the 2024 International Photodynamic and Photodiagnosis Conference.
Yahong Pharmaceuticals (688176.SH) announced that recently, the company's product APL-1702 is used to treat advanced cervical cancer...
Yahong Medicine (688176.SH) released its semi-annual performance, with a net loss of 0.184 billion yuan.
Yahong Pharmaceutical (688176.SH) disclosed its 2024 interim report. During the reporting period, the company achieved revenue of 8,049...
Jiangsu Yahong Pharmaceutical Technology Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiangsu Yahong Pharmaceutical Technology Co., Ltd.
Yahong Medicine (688176.SH): plans to launch a restricted stock incentive plan for 8.3201 million shares.
Gelonghui announced on August 28th that YAHong Pharmaceuticals (688176.SH) has released a restricted stock incentive plan for 2024. The plan plans to grant 8.3201 million restricted stocks to the incentive recipients, accounting for approximately 1.46% of the total shares of the company's capital, which was 570 million shares at the time of the announcement of the incentive plan draft. The grant is a one-time grant with no reserved portions.
Yuhong Pharmaceutical (688176.SH): The revenue in Q2 of 2024 increased by 130.98% month-on-month, and the core products are steadily progressing to market.
On August 28, YAHONG Medicine (688176.SH) released its 2024 interim report. In the first half of 2024, the company achieved revenue of 80.4934 million yuan, with 56.1739 million yuan achieved in the second quarter, a 130.98% increase compared to the previous quarter. In addition, the company is actively promoting the market launch of two core products. The new drug application for APL-1702 has been accepted, and the company is actively advancing the market approval process. Currently, the progress is smooth, and it is expected to become the world's first non-surgical treatment for high-grade squamous intraepithelial lesions of the cervix. APL-1706 has also successfully passed the national drug approval process.
YaHong Medical (688176.SH): has repurchased 1.3608% of the shares.
On August 1st, Gelonhui announced that as of July 31, 2024, the company had cumulatively repurchased 7,756,291 shares, accounting for 1.3608% of the total share capital, with a maximum repurchase price of RMB 6.73 per share, and a minimum price of RMB 5.02 per share. The total amount paid was RMB 44.79 million (excluding stamp duty, transaction commission and other trading expenses).
Yahong Medicine (688176.SH): has repurchased 1.0685% of the shares cumulatively.
On July 3rd, Gelonhui reported that Yahong Medicine (688176.SH) has cumulatively repurchased 6,090,403 shares through centralized bidding trading as of July 3, 2024, accounting for 1.0685% of the total equity of the company. Compared with the previous disclosure, the proportion has increased by 0.4419%. The highest price for repurchase transactions was RMB 6.73 per share, the lowest price was RMB 5.08 per share, and the total amount paid was RMB 36,196,800 (excluding stamp duty, transaction commissions, and other transaction costs).
Yahong Pharmacy (688176.SH): the actual controller and financial person in charge have completed the shareholding, costing 4 million yuan.
Yahong Pharmaceutical (688176.SH) announced that as of July 2, 2024, the company's controlling shareholder and actual controller...
No Data
